Obesity and GLP-1 RAs

The CardioNerds Cardiovascular Prevention Series dives into Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs). This class of medications is becoming a household name, not only for their implications for weight loss but also for their effect on cardiovascular disease. This series also highlights the impact of obesity on cardiovascular disease risk, differential risk in specific populations, and effective strategies for counseling patients. This series is supported by unrestricted educational sponsorship from Novo Nordisk. All CardioNerds content is planned, produced, and reviewed solely by CardioNerds.

GLP-1 Agonists: Mechanisms to Applications with Dr. Dennis Bruemmer

Obesity: Obesity & Cardiovascular Disease Risk with Dr. Jaime Almandoz

Obesity: Lifestyle & Pharmacologic Management of Obesity with Dr. Ambarish Pandey

GLP-1 Agonists: Diving into the Data with Dr. Darren McGuire

GLP-1 Agonists: Clinical Implementation of GLP-1 Receptor Agonists with Dr. Neha Pagidapati

Obesity: Procedural Management of Obesity with Dr. Steve Nissen